{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:40:45Z","timestamp":1777934445364,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T00:00:00Z","timestamp":1595116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-small-cell lung carcinoma (NSCLC) accounts for 85\u201390% of all forms of lung cancer. Immuno-oncology represents a valid new approach but the high cost requires a specific evaluation of the health outcomes. This study describes the real-world efficacy, safety and cost profiles of the new anti-PD-1 immune-checkpoint inhibitors nivolumab and pembrolizumab on a cohort of 56 selected patients with advanced NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, observational analysis was conducted on patients treated with immune checkpoint inhibitors from September 2015 to September 2018 at Azienda Ospedaliera Universitaria \u201cMater Domini\u201d in Catanzaro, Italy. Data sources were medical records, internal prescription cards and reports of adverse reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-six patients were diagnosed with advanced NSCLC, 64.3% characterized by a non-squamous histology, 30.3% squamous and 5.4% not specified. First-line treatment with pembrolizumab was administered to 11 patients for an average of 4.4\u2009months, while 45 patients were treated with nivolumab for an average of 8.6\u2009months. Data showed a survival rate of 95% after 6\u2009months and 88% after 12\u2009months. Most patients received immunotherapy as a second-line or subsequent treatment. In terms of prior therapy among all the patients, 43 had received platinum-based treatments. Indirect comparison with other real-world data studies showed variability in methodologies and an alignment in terms of results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study, based on real-world data, was a first step in the assessment of the impact of the introduction of a significant new class of treatments, i.e. immunotherapy, and covers patients, treatments and outcomes, as well as organizational and economic variables.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220941586","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T02:49:42Z","timestamp":1595213382000},"page":"877-886","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world data on patients with metastatic non-small-cell lung cancer treated with checkpoint inhibitors in an Italian Teaching Hospital in 2015\u20132018"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-1522","authenticated-orcid":false,"given":"Marianna","family":"Veraldi","sequence":"first","affiliation":[{"name":"Pharmacy Unit, \u201cMater Domini\u201d University Hospital, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Esposito","sequence":"additional","affiliation":[{"name":"Pharmacy Unit, \u201cMater Domini\u201d University Hospital, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria D.","family":"Naturale","sequence":"additional","affiliation":[{"name":"Graduate School of Health Economics and Management (ALTEMS), Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Oradei","sequence":"additional","affiliation":[{"name":"Health Technology Assessment Unit, Fondazione Policlinico Universitario \u201cA. Gemelli\u201d IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Cosco","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Gr\u00e6cia\u201d of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele E. De","family":"Francesco","sequence":"additional","affiliation":[{"name":"Pharmacy Unit, \u201cMater Domini\u201d University Hospital, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Americo","family":"Cicchetti","sequence":"additional","affiliation":[{"name":"Graduate School of Health Economics and Management (ALTEMS), Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella Di","family":"Bidino","sequence":"additional","affiliation":[{"name":"Health Technology Assessment Unit, Fondazione Policlinico Universitario \u201cA. Gemelli\u201d IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,7,19]]},"reference":[{"key":"bibr1-1078155220941586","unstructured":"AIOM. I numeri del cancro in Italia [Cancer numbers in Italy]. Report AIOM-AIRTUM, https:\/\/www.aiom.it\/linee-guida-aiom-neoplasie-del-polmone-2019\/ (2019, accessed 29 June 2020)."},{"key":"bibr2-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.07.020"},{"key":"bibr3-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.041"},{"key":"bibr4-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.04.004"},{"key":"bibr5-1078155220941586","first-page":"990","volume":"380","author":"Antonia SJ.","year":"2017","journal-title":"N Engl J Med"},{"key":"bibr6-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954"},{"key":"bibr7-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181f7c6d4"},{"key":"bibr8-1078155220941586","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0062"},{"key":"bibr9-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"bibr10-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"bibr11-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"bibr12-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy474"},{"key":"bibr13-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"bibr14-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0353"},{"key":"bibr15-1078155220941586","doi-asserted-by":"publisher","DOI":"10.7150\/jca.24985"},{"key":"bibr16-1078155220941586","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.04.03"},{"key":"bibr17-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40748-7"},{"key":"bibr18-1078155220941586","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2015-0043"},{"key":"bibr19-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2720"},{"key":"bibr20-1078155220941586","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.09.15"},{"key":"bibr21-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.10.005"},{"key":"bibr22-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.07.009"},{"key":"bibr23-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.04.010"},{"key":"bibr24-1078155220941586","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1684\/ejd.2017.3192","volume":"28","author":"Oya K","year":"2018","journal-title":"Eur J Dermatol"},{"key":"bibr25-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4427"},{"key":"bibr26-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001107"},{"key":"bibr27-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0167-7"},{"key":"bibr28-1078155220941586","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033040"},{"key":"bibr29-1078155220941586","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4555"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220941586","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220941586","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220941586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:22Z","timestamp":1777688602000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220941586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,19]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1177\/1078155220941586"],"URL":"https:\/\/doi.org\/10.1177\/1078155220941586","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,19]]}}}